D. Gernhardt

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

G. Giaccone, P. Jänne, F. Khuri, 2014, Cancer.

Peristaltic pressure profiles of the human esophagus.

G. Meyer, D. Castell, D. Gernhardt, 2000, Journal of clinical gastroenterology.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

T. Mok, Yi-long Wu, K. Nakagawa, 2019, Future oncology.

Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2020 .

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

N. Robert, John W. Davis, K. Kern, 2011, Clinical Breast Cancer.

Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.

M. Lacouture, A. Jatoi, S. Sonis, 2015 .

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

M. Lacouture, Dong-Wan Kim, B. Cho, 2017, Lung cancer.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

M. Lacouture, A. Jatoi, S. Sonis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.